mitomycin has been researched along with Carcinoma in Situ in 153 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS)." | 9.22 | Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. ( Jahnson, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2016) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 9.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 9.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 9.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 9.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "Therapy of carcinoma in situ with alternating mitomycin C and BCG is more effective than mitomycin C alone." | 9.08 | Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Rajala, P; Rintala, E; Ruutu, M, 1995) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 9.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 9.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 9.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 8.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 7.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| " In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops." | 7.71 | [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 7.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 7.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 7.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 7.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 7.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 7.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 7.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C." | 7.68 | Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ. ( Amano, T; Hisazumi, H; Koshida, K; Kunimi, K; Morishita, H; Naito, K, 1993) |
| "During long periods of buffered instillations of mitomycin C (MMC) and doxorubicin (adriamycin; ADM) on carcinoma in situ (TIS), the complete response was 82% for MMC and 80% for ADM." | 7.67 | Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. ( Alfthan, O; Jauhiainen, K; Permi, J; Sotarauta, M, 1986) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 7.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 7.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 7.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 6.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 6.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 5.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42±2°C) or control following stratification for carcinoma in situ (CIS) status (present/absent), therapy history (failure of previous induction/maintenance BCG), and treatment centre." | 5.30 | Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th ( Bhatt, R; Billingham, LJ; Buckley, L; Cresswell, J; Datta, SN; Devall, AJ; Feneley, MR; Griffiths, TRL; Hodgson, D; Issa, R; Kelly, JD; Loubière, LS; Madaan, S; McGrath, J; Mostafid, H; Page, T; Panchal, A; Pope, AM; Sangar, V; Tan, WS, 2019) |
| "The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS)." | 5.22 | Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. ( Jahnson, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2016) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 5.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 5.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 5.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "Therapy of carcinoma in situ with alternating mitomycin C and BCG is more effective than mitomycin C alone." | 5.08 | Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Rajala, P; Rintala, E; Ruutu, M, 1995) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 5.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 5.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 5.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 5.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 4.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "Hyperthermic mitomycin (HM) is a novel treatment modality for selected patients with high-risk non-muscle invasive bladder cancer (NMIBC)." | 3.83 | Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients. ( Ayres, BE; Bailey, M; Chiocchia, V; Dutton, S; Issa, R; Le Roux, P; Pai, A; Perry, MJ; Sooriakumaran, P; Swinn, M, 2016) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 3.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| " A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8." | 3.72 | Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. ( Hausladen, DA; Sheryka, E; Weiss, RM; Wheeler, MA, 2003) |
| " In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops." | 3.71 | [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 3.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 3.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 3.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 3.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "At the Institute of Urology, University of Padova, 125 patients with multifocal superficial bladder cancer underwent treatment with intravesical Mitomycin C (MMC; 1 weekly instillation of 40 mg for 8 consecutive weeks) between January 1982 and December 1988." | 3.68 | Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results. ( Bassi, P; Drago-Ferrante, GL; Garbeglio, A; Maruzzi, D; Meneghini, A; Milani, C; Pagano, F; Piazza, N; Zattoni, F, 1992) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 3.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 3.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 3.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C." | 3.68 | Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ. ( Amano, T; Hisazumi, H; Koshida, K; Kunimi, K; Morishita, H; Naito, K, 1993) |
| "We present a series of 13 patients with diffuse carcinoma in situ (CIS) of the bladder who failed an initial induction course of intravesical therapy with Mitomycin C, thiotepa, doxorubicin or Bacillus Calmette Guérin (BCG)." | 3.67 | Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. ( deKernion, JB; Mukamel, E, 1989) |
| "During long periods of buffered instillations of mitomycin C (MMC) and doxorubicin (adriamycin; ADM) on carcinoma in situ (TIS), the complete response was 82% for MMC and 80% for ADM." | 3.67 | Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. ( Alfthan, O; Jauhiainen, K; Permi, J; Sotarauta, M, 1986) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 3.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 3.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 3.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| " Time of resolution and frequency of adverse effects were analyzed to determine the pharmacological efficacy and safety of both medications." | 3.30 | Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy. ( Alvarado-Castillo, B; Garcia-Benavides, L; Gonzalez-Castillo, C; Navarro-Partida, J; Rosales-Gradilla, ME; Santa Cruz-Pavlovich, FJ; Vidal-Paredes, IA, 2023) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 2.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 2.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "Ablation of high-grade bladder tumors is feasible, achieving a complete response in about three quarters of the patients." | 2.71 | Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "There was no disease progression in either treatment arm at three months' follow-up." | 2.55 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer. ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "Mitomycin C has been shown in studies to be highly effective but has short-term and long-term side-effects that may be intolerable." | 2.49 | Topical chemotherapy for ocular surface squamous neoplasia. ( Karp, CL; Nanji, AA; Sayyad, FE, 2013) |
| "Non-muscle-invasive bladder cancers form a heterogeneous group of tumours with varying recurrence and progression rates." | 2.45 | Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. ( Horvath, A; Mostafid, H, 2009) |
| "Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers." | 2.41 | An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. ( Duque, JL; Loughlin, KR, 2000) |
| " Different dosage schedules and methods require further study." | 2.38 | Intravesical chemotherapy. Treatment selection, techniques, and results. ( Richie, JP, 1992) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "For females without known risk factors, bladder cancer can be regarded as a sentinel environmental cancer." | 1.91 | Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. ( Armstrong, J; Davis, D; Kogan, M; Lowe, P; Meng, M; Morash, C; Seely, D, 2023) |
| "Two of eight patients (25 %) with squamous cell carcinoma (SCC) had positive lateral margins." | 1.39 | Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva. ( Arvas, S; Pazarli, H; Sarici, AM, 2013) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 1.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "DNA cytometry showed nonaneuploidy in all of these." | 1.30 | Cytologic and DNA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in situ and malignant melanoma of the cornea and conjunctiva. ( Böcking, A; Kersten, A; Krallmann, R; Motherby, H; Nadjari, B; Ross, B; Sundmacher, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (25.49) | 18.7374 |
| 1990's | 39 (25.49) | 18.2507 |
| 2000's | 42 (27.45) | 29.6817 |
| 2010's | 28 (18.30) | 24.3611 |
| 2020's | 5 (3.27) | 2.80 |
| Authors | Studies |
|---|---|
| Moratal Peiro, B | 1 |
| Calvo Garcia, R | 1 |
| Soler Sanchis, I | 1 |
| Mata Moret, L | 1 |
| Cervera Taulet, E | 1 |
| Davis, D | 1 |
| Seely, D | 1 |
| Morash, C | 1 |
| Armstrong, J | 1 |
| Meng, M | 1 |
| Lowe, P | 1 |
| Kogan, M | 1 |
| Alvarado-Castillo, B | 1 |
| Santa Cruz-Pavlovich, FJ | 1 |
| Gonzalez-Castillo, C | 1 |
| Vidal-Paredes, IA | 1 |
| Garcia-Benavides, L | 1 |
| Rosales-Gradilla, ME | 1 |
| Navarro-Partida, J | 1 |
| Pierconti, F | 1 |
| Martini, M | 1 |
| Fiorentino, V | 1 |
| Cenci, T | 1 |
| Capodimonti, S | 1 |
| Straccia, P | 1 |
| Sacco, E | 1 |
| Pugliese, D | 1 |
| Cindolo, L | 1 |
| Larocca, LM | 1 |
| Bassi, PF | 2 |
| Minot, M | 1 |
| Gonzalvez, M | 1 |
| Denis, D | 1 |
| David, T | 1 |
| Jung, JH | 1 |
| Gudeloglu, A | 1 |
| Kiziloz, H | 1 |
| Kuntz, GM | 1 |
| Miller, A | 1 |
| Konety, BR | 1 |
| Dahm, P | 1 |
| Blasi, MA | 1 |
| Maceroni, M | 1 |
| Sammarco, MG | 1 |
| Pagliara, MM | 1 |
| Balasubramanian, A | 1 |
| Metcalfe, MJ | 1 |
| Wagenheim, G | 1 |
| Xiao, L | 1 |
| Papadopoulos, J | 1 |
| Navai, N | 1 |
| Davis, JW | 1 |
| Karam, JA | 1 |
| Kamat, AM | 1 |
| Wood, CG | 1 |
| Dinney, CP | 1 |
| Matin, SF | 1 |
| Tan, WS | 1 |
| Panchal, A | 1 |
| Buckley, L | 1 |
| Devall, AJ | 1 |
| Loubière, LS | 1 |
| Pope, AM | 1 |
| Feneley, MR | 1 |
| Cresswell, J | 1 |
| Issa, R | 2 |
| Mostafid, H | 2 |
| Madaan, S | 1 |
| Bhatt, R | 1 |
| McGrath, J | 1 |
| Sangar, V | 1 |
| Griffiths, TRL | 1 |
| Page, T | 1 |
| Hodgson, D | 1 |
| Datta, SN | 1 |
| Billingham, LJ | 1 |
| Kelly, JD | 1 |
| Herwig-Carl, MC | 1 |
| Grossniklaus, HE | 2 |
| Müller, PL | 1 |
| Atzrodt, L | 1 |
| Loeffler, KU | 1 |
| Auw-Haedrich, C | 1 |
| Nanji, AA | 1 |
| Sayyad, FE | 1 |
| Karp, CL | 2 |
| Sarici, AM | 1 |
| Arvas, S | 1 |
| Pazarli, H | 1 |
| Lee, JH | 1 |
| Kim, YH | 1 |
| Kim, MS | 1 |
| Kim, EC | 1 |
| Kim, BH | 1 |
| Kim, MK | 1 |
| Wee, WR | 1 |
| Oh, JY | 1 |
| Besley, J | 1 |
| Pappalardo, J | 1 |
| Lee, GA | 1 |
| Hirst, LW | 2 |
| Vincent, SJ | 1 |
| de la Cruz Aguiló, RI | 1 |
| Duch-Samper, A | 1 |
| Hernández Pérez, D | 1 |
| Marí Cotino, J | 1 |
| Sooriakumaran, P | 1 |
| Chiocchia, V | 1 |
| Dutton, S | 1 |
| Pai, A | 1 |
| Ayres, BE | 1 |
| Le Roux, P | 1 |
| Swinn, M | 1 |
| Bailey, M | 1 |
| Perry, MJ | 1 |
| Shelley, M | 1 |
| Court, JB | 2 |
| Kynaston, HG | 1 |
| Wilt, TJ | 2 |
| Coles, B | 2 |
| Mason, M | 2 |
| Shah, KJ | 1 |
| Mogilishetty, G | 1 |
| Holland, EJ | 2 |
| Arends, TJ | 1 |
| Nativ, O | 3 |
| Maffezzini, M | 1 |
| de Cobelli, O | 1 |
| Canepa, G | 1 |
| Verweij, F | 1 |
| Moskovitz, B | 1 |
| van der Heijden, AG | 2 |
| Witjes, JA | 5 |
| Kaasinen, E | 5 |
| Wijkström, H | 2 |
| Rintala, E | 7 |
| Mestad, O | 2 |
| Jahnson, S | 1 |
| Malmström, PU | 2 |
| Esuvaranathan, K | 1 |
| Porubská, K | 1 |
| Rohrbach, JM | 1 |
| Irani, J | 1 |
| Schallenberg, M | 1 |
| Niederdräing, N | 1 |
| Steuhl, KP | 1 |
| Meller, D | 1 |
| Mazerolles, C | 1 |
| Horvath, A | 1 |
| Alfred Witjes, J | 1 |
| Hendricksen, K | 1 |
| Gofrit, O | 1 |
| Risi, O | 1 |
| Gentile, CM | 1 |
| Burchakchi, AI | 1 |
| Oscar, CJ | 1 |
| Zaki, AA | 1 |
| Farid, SF | 1 |
| Wada, H | 1 |
| Nakano, Y | 1 |
| Yamada, H | 1 |
| Saiga, T | 1 |
| Yamanaka, A | 1 |
| Sakai, N | 1 |
| Gupta, A | 1 |
| Muecke, J | 3 |
| Verma, A | 1 |
| Degrado, J | 1 |
| Hittelman, AB | 1 |
| Wheeler, MA | 2 |
| Kaimakliotis, HZ | 1 |
| Weiss, RM | 2 |
| Birkholz, ES | 1 |
| Goins, KM | 1 |
| Sutphin, JE | 2 |
| Kitzmann, AS | 1 |
| Wagoner, MD | 1 |
| Sugandhi, P | 1 |
| George, RE | 1 |
| Oosterlinck, W | 1 |
| Kirkali, Z | 1 |
| Sylvester, R | 1 |
| da Silva, FC | 1 |
| Busch, C | 1 |
| Algaba, F | 1 |
| Collette, S | 1 |
| Bono, A | 1 |
| Gokhale, NS | 1 |
| Ooi, WL | 1 |
| Stockler, M | 1 |
| Hayne, D | 1 |
| Nishikawa, N | 1 |
| Hanada, K | 1 |
| Miyokawa, N | 1 |
| Tokusashi, Y | 1 |
| Yoshida, A | 1 |
| Galor, A | 1 |
| Oellers, P | 1 |
| Kao, AA | 1 |
| Abdelaziz, A | 1 |
| Feuer, W | 1 |
| Dubovy, SR | 1 |
| Järvinen, R | 1 |
| Group, TF | 1 |
| Papandroudis, AA | 1 |
| Dimitrakos, SA | 1 |
| Stangos, NT | 1 |
| Panda, A | 1 |
| Sudan, R | 1 |
| Rodríguez-Pérez, C | 1 |
| Del Campo, Z | 1 |
| Wolley-Dod, C | 1 |
| Gris, O | 1 |
| Hellsten, S | 2 |
| Duchek, M | 1 |
| Sheryka, E | 1 |
| Hausladen, DA | 1 |
| Snyder, ME | 1 |
| Di Stasi, SM | 1 |
| Giannantoni, A | 1 |
| Stephen, RL | 1 |
| Capelli, G | 1 |
| Navarra, P | 1 |
| Massoud, R | 1 |
| Vespasiani, G | 1 |
| Shelley, MD | 1 |
| Kynaston, H | 1 |
| Rosner, M | 1 |
| Hadar, I | 1 |
| Rosen, N | 1 |
| Chen, C | 1 |
| Louis, D | 1 |
| Dodd, T | 1 |
| Di Pascuale, MA | 1 |
| Espana, EM | 1 |
| Tseng, SC | 1 |
| Gofrit, ON | 1 |
| Shapiro, A | 1 |
| Pode, D | 1 |
| Sidi, A | 1 |
| Leib, Z | 1 |
| Naspro, R | 1 |
| Colombo, R | 1 |
| Dudney, BW | 1 |
| Malecha, MA | 1 |
| Ito, M | 1 |
| Habuchi, T | 1 |
| Watanabe, J | 1 |
| Higashi, S | 1 |
| Nishiyama, H | 1 |
| Wang, L | 1 |
| Tsuchiya, N | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Ramos-López, JF | 1 |
| Martínez-Costa Pérez, R | 1 |
| Cisneros Lanuza, AL | 1 |
| Francés Muñoz, E | 1 |
| Monte Boque, E | 1 |
| Muñoz Gómez, MC | 1 |
| López-Sánchez, EV | 1 |
| Menezo Rozalén, JL | 1 |
| Prabhasawat, P | 1 |
| Tarinvorakup, P | 1 |
| Tesavibul, N | 1 |
| Uiprasertkul, M | 1 |
| Kosrirukvongs, P | 1 |
| Booranapong, W | 1 |
| Srivannaboon, S | 1 |
| Singh, AD | 1 |
| Jacques, R | 1 |
| Rundle, PA | 1 |
| Rennie, IG | 1 |
| Mudhar, HS | 1 |
| Slater, D | 1 |
| Laria-Ochaita, C | 1 |
| Alió-y-Sanz, JL | 1 |
| Khong, JJ | 1 |
| Huerva, V | 1 |
| Mateo, AJ | 1 |
| Mangues, I | 1 |
| Jurjo, C | 1 |
| Ozcan, AA | 1 |
| Sizmaz, S | 1 |
| Yagmur, M | 1 |
| Pournaras, JA | 1 |
| Chamot, L | 1 |
| Uffer, S | 1 |
| Zografos, L | 1 |
| Balestrazzi, A | 1 |
| Martone, G | 1 |
| Pichierri, P | 1 |
| Tosi, GM | 1 |
| Caporossi, A | 1 |
| Spaulding, JT | 1 |
| Paulson, DF | 1 |
| Lum, BL | 1 |
| Murphy, WM | 4 |
| Friedell, GH | 1 |
| Harrison, GS | 1 |
| Green, DF | 1 |
| Newling, DW | 3 |
| Richards, B | 2 |
| Robinson, MR | 3 |
| Smith, PH | 2 |
| Jakse, G | 1 |
| Soloway, MS | 7 |
| DeFuria, MD | 2 |
| Crooke, S | 1 |
| Finebaum, P | 1 |
| Flüchter, SH | 3 |
| Bichler, KH | 3 |
| Harzmann, R | 3 |
| Erdmann, D | 2 |
| Hlobil, H | 1 |
| Erdmann, W | 1 |
| Prout, GR | 1 |
| Griffin, PP | 1 |
| Nocks, BN | 1 |
| Daly, JJ | 1 |
| Hofmann, W | 1 |
| Langkopf, B | 1 |
| Manyak, MJ | 1 |
| Sekine, H | 6 |
| Fukui, I | 6 |
| Yamada, T | 5 |
| Kojima, S | 1 |
| Ohshima, H | 2 |
| Jauhiainen, K | 5 |
| Rajala, P | 1 |
| Ruutu, M | 2 |
| Alfthan, O | 5 |
| Vegt, PD | 1 |
| Witjes, WP | 3 |
| Doesburg, WH | 2 |
| Debruyne, FM | 6 |
| van der Meijden, AP | 2 |
| Minervini, R | 2 |
| Felipetto, R | 2 |
| Viganò, L | 2 |
| Cecchi, M | 2 |
| Frucht-Pery, J | 3 |
| Rozenman, Y | 3 |
| Pagni, G | 1 |
| Mulders, PF | 1 |
| Meyden, AP | 1 |
| Oosterhof, GO | 1 |
| Ohwada, F | 2 |
| Yokokawa, M | 2 |
| Boccardo, F | 1 |
| Cannata, D | 1 |
| Rubagotti, A | 1 |
| Guarneri, D | 1 |
| Decensi, A | 1 |
| Canobbio, L | 1 |
| Curotto, A | 1 |
| Martorana, G | 1 |
| Pegoraro, C | 1 |
| Selvaggi, F | 1 |
| Amano, T | 1 |
| Naito, K | 1 |
| Koshida, K | 1 |
| Kunimi, K | 1 |
| Morishita, H | 1 |
| Hisazumi, H | 1 |
| vd Meijden, AP | 1 |
| Doesburg, W | 3 |
| Schaafsma, HE | 1 |
| Vinnicombe, SJ | 1 |
| MacVicar, AD | 1 |
| Guy, RL | 1 |
| Sloane, JP | 1 |
| Powles, TJ | 1 |
| Knee, G | 1 |
| Husband, JE | 1 |
| Iavarone, C | 1 |
| Minocchi, L | 1 |
| Arecchi, S | 1 |
| Nicolucci, D | 1 |
| Porcelli, C | 1 |
| D'orazi, V | 1 |
| Greco, L | 1 |
| Stio, F | 1 |
| Martino, G | 1 |
| Messinetti, S | 1 |
| Tseng, SH | 1 |
| Tsai, YY | 1 |
| Chen, FK | 1 |
| Sugar, J | 1 |
| Baum, J | 1 |
| Pe'er, J | 1 |
| Savir, H | 1 |
| Meisler, DM | 1 |
| Foster, JA | 1 |
| Folberg, R | 1 |
| Wilson, MW | 2 |
| Hungerford, JL | 1 |
| George, SM | 1 |
| Madreperla, SA | 1 |
| Aaberg, TM | 1 |
| Heigle, TJ | 1 |
| Stulting, RD | 1 |
| Palay, DA | 1 |
| Gebhardt, DO | 1 |
| Haas, K | 1 |
| Ben-Dor, D | 1 |
| Levartovsky, S | 1 |
| Nadjari, B | 2 |
| Kersten, A | 2 |
| Ross, B | 1 |
| Motherby, H | 1 |
| Krallmann, R | 1 |
| Sundmacher, R | 2 |
| Böcking, A | 2 |
| Duque, JL | 1 |
| Loughlin, KR | 1 |
| Schelonka, LP | 1 |
| Siegel, D | 1 |
| Meininger, A | 1 |
| Ross, D | 1 |
| Montie, JE | 1 |
| Joseph, A | 1 |
| Sabri, K | 1 |
| Dua, HS | 1 |
| Cartsburg, O | 1 |
| Pomjanski, N | 1 |
| Ohya, K | 1 |
| Kojima, SI | 1 |
| Igarashi, K | 1 |
| Siganos, CS | 1 |
| Kozobolis, VP | 1 |
| Christodoulakis, EV | 1 |
| Yamamoto, N | 1 |
| Ohmura, T | 1 |
| Suzuki, H | 1 |
| Shirasawa, H | 1 |
| Daniell, M | 1 |
| Maini, R | 1 |
| Tole, D | 1 |
| van der Meijden, PM | 2 |
| Roos, EP | 1 |
| Steerenberg, PA | 3 |
| Kihara, K | 3 |
| Tachibana, Y | 1 |
| Kawai, T | 3 |
| Ishiwata, D | 2 |
| Oshima, H | 1 |
| Pagano, F | 2 |
| Bassi, P | 2 |
| Milani, C | 3 |
| Piazza, N | 2 |
| Meneghini, A | 3 |
| Garbeglio, A | 3 |
| Droller, MJ | 2 |
| Flanigan, RC | 1 |
| Nseyo, UO | 1 |
| Zattoni, F | 2 |
| Maruzzi, D | 1 |
| Drago-Ferrante, GL | 1 |
| Richie, JP | 1 |
| Brosman, SA | 1 |
| Jauhiainen, KE | 1 |
| Alfthan, OS | 1 |
| Solsona, E | 2 |
| Iborra, I | 2 |
| Ricós, JV | 2 |
| Monrós, JL | 2 |
| Dumont, R | 2 |
| Casanova, J | 2 |
| Calabuig, C | 2 |
| Pisters, LL | 1 |
| Tykochinsky, G | 1 |
| Wajsman, Z | 1 |
| Stricker, PD | 2 |
| Grant, AB | 2 |
| Hosken, BM | 2 |
| Taylor, JS | 2 |
| Månsson, W | 1 |
| Henrikson, H | 1 |
| Idwall, I | 1 |
| Lindholm, K | 1 |
| Mikulowski, P | 1 |
| Mårtensson, S | 1 |
| Oldbring, J | 1 |
| Prescott, S | 1 |
| James, K | 1 |
| Hargreave, TB | 1 |
| Chisholm, GD | 1 |
| Smyth, JF | 1 |
| Torti, FM | 1 |
| Takeuchi, S | 1 |
| Hosoda, K | 2 |
| Suzuki, S | 1 |
| Giesbers, AA | 1 |
| Van Helsdingen, PJ | 2 |
| Kramer, AE | 1 |
| Mukamel, E | 1 |
| deKernion, JB | 1 |
| Jordan, AM | 1 |
| de Jong, WH | 2 |
| Biserte, J | 1 |
| Rigot, JM | 1 |
| Mauroy, B | 1 |
| Mazeman, E | 1 |
| Farha, AJ | 1 |
| Krauss, DJ | 1 |
| Giunta, A | 1 |
| Tejerizo, JC | 1 |
| dal Bianco, M | 1 |
| Sotarauta, M | 1 |
| Permi, J | 1 |
| Blatnik, AF | 1 |
| Shelton, TB | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Perry, A | 1 |
| Smith, AY | 1 |
| Vitale, PJ | 1 |
| Lowe, BA | 1 |
| Woodside, JR | 1 |
| Washizuka, M | 1 |
| Oka, K | 1 |
| Ikegami, S | 1 |
| Rikken, CH | 1 |
| Sleeboom, HP | 1 |
| de Bruyn, EA | 1 |
| Tjaden, UR | 1 |
| Jenkins, BJ | 1 |
| England, HR | 1 |
| Fowler, CG | 1 |
| Tiptaft, RC | 1 |
| Badenoch, DF | 1 |
| Paris, AM | 1 |
| Oliver, RT | 1 |
| Blandy, JP | 1 |
| Schreinemachers, LM | 1 |
| Geboers, AD | 1 |
| Franssen, MP | 1 |
| van Leeuwen, MJ | 1 |
| Ruitenberg, EJ | 1 |
| Cooper, EH | 1 |
| Yu, H | 1 |
| Glashan, RW | 1 |
| Zincke, H | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Taylor, WF | 1 |
| Walsh, PC | 1 |
| Somerville, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bac[NCT01094964] | Phase 3 | 242 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)[NCT00384891] | Phase 3 | 190 participants (Actual) | Interventional | 2002-02-28 | Terminated (stopped due to slow accrual) | ||
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-01 | Active, not recruiting | ||
| The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer[NCT03790384] | Phase 4 | 140 participants (Anticipated) | Interventional | 2019-01-15 | Not yet recruiting | ||
| A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder[NCT00023842] | Phase 2 | 97 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management[NCT00343356] | Phase 2 | 138 participants | Interventional | 1996-06-30 | Completed | ||
| Pilot Study: Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging[NCT02798484] | 61 participants (Actual) | Interventional | 2016-06-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for mitomycin and Carcinoma in Situ
| Article | Year |
|---|---|
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2017 |
Topical chemotherapy for ocular surface squamous neoplasia.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; | 2013 |
WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2015 |
Ocular Surface Squamous Neoplasia in a Living-Related Conjunctival Limbal Allograft.
Topics: Aged; Allografts; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; Conjunc | 2016 |
[Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Topics: Adjuvants, Immunologic; Age Factors; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Si | 2008 |
[Topical Mitomycin C as a therapy of conjunctival tumours].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2008 |
Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Disease Progres | 2009 |
Treatment of ocular surface squamous neoplasia with Mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuva | 2010 |
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2003 |
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Treatment of superficial carcinoma of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Carcinoma in Situ; Carcinoma, Transitional Cell; Comb | 1984 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
Current topics in the pathology of bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Chromosome Aberrations; Chromosomes, Human, 1-3; Cy | 1983 |
An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
Intravesical chemotherapy. Treatment selection, techniques, and results.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell | 1992 |
Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
Intravesical mitomycin C and superficial bladder tumors.
Topics: Administration, Intravesical; Carcinoma in Situ; Humans; Instillation, Drug; Mitomycin; Mitomycins; | 1989 |
Introduction and overview of intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubi | 1988 |
41 trials available for mitomycin and Carcinoma in Situ
| Article | Year |
|---|---|
Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Topics: Administration, Topical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunc | 2023 |
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma | 2019 |
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Treatment of ocular surface squamous neoplasia with Mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuva | 2010 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2012 |
Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2004 |
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma | 2004 |
Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in S | 2007 |
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
[Clinical trials with localized mitomycin instillation therapy for superficial urothelial bladder carcinoma].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Follow-Up St | 1982 |
Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 1995 |
A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Follow-Up Studie | 1995 |
Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Carcin | 1994 |
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillar | 1994 |
Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1993 |
A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Cy | 1993 |
Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Car | 1996 |
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in S | 1997 |
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 2001 |
Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in S | 2002 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; | 1992 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 1992 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined | 1991 |
Recurrence of superficial bladder tumors in prostatic urethra.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma in Si | 1991 |
Carcinoma in situ associated with superficial bladder tumor.
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; Carcinoma in S | 1991 |
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papi | 1990 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transiti | 1989 |
Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Drug Administration Schedule; Follow-U | 1989 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Cystitis; Humans | 1989 |
[Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Papillary; Clinical Trials as Topic; Dru | 1989 |
Mitomycin C resorption following repeated intravesical instillations using different instillation times.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials | 1988 |
BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1988 |
Proteinuria after intravesical chemotherapy.
Topics: Carcinoembryonic Antigen; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomyci | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
95 other studies available for mitomycin and Carcinoma in Situ
| Article | Year |
|---|---|
Advancing wavelike epitheliopathy after conjunctival intraepithelial neoplasia. Atipical case report.
Topics: Administration, Topical; Carcinoma in Situ; Conjunctival Neoplasms; Corneal Diseases; Humans; Mitomy | 2022 |
Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinogens; Carcinoma in Situ; Female; Humans; Mal | 2023 |
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2021 |
[Impressive regression of a conjunctival carcinoma with topical mitomycin C].
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctiva; Conjunct | 2021 |
Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Alkylating Agents; Carcinoma in Situ; Ca | 2018 |
Salvage topical therapy for upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG | 2018 |
Pyogenic granuloma associated with conjunctival epithelial neoplasia: report of nine cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcino | 2019 |
Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous | 2013 |
The effect of surgical wide excision and amniotic membrane transplantation with adjuvant topical mitomycin C treatment in recurrent conjunctival--corneal intraepithelial neoplasia.
Topics: Aged; Alkylating Agents; Amnion; Carcinoma in Situ; Combined Modality Therapy; Conjunctival Neoplasm | 2014 |
Clinical and pathological characteristics of ocular surface squamous neoplasia in an Asian population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma in Situ; Carcinoma, S | 2013 |
Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Conjunctival intraepithelial neoplasia. Interferon as a rescue therapy after failure of mitomycin C.
Topics: Antineoplastic Agents; Carcinoma in Situ; Conjunctival Neoplasms; Drug Resistance, Neoplasm; Drug Su | 2014 |
Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
Topics: Aged; Antibiotics, Antineoplastic; Biopsy; Carcinoma in Situ; Cohort Studies; Cystectomy; Cystoscopy | 2016 |
Editorial comments on: Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder, by E. Kaasinen et al. (in this i
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Follow-Up Stud | 2016 |
[Unclear monocular chronic reddening of the conjunctiva with ptosis].
Topics: Antibiotics, Antineoplastic; Blepharoptosis; Carcinoma in Situ; Conjunctival Neoplasms; Follow-Up St | 2008 |
[Case 4. Perspectives in 2007 for bladder pathology. Giant cell urothelial carcinoma in situ].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Diagnosis, Differential; Humans; Immunohistoch | 2008 |
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; | 2009 |
In vivo confocal microscopy study of ocular surface neoplasia manifesting after radial keratotomy and laser in situ keratomileusis.
Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival Neoplasms; Corn | 2009 |
Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
Topics: Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy | 2009 |
Intravesical mitomycin-C-induced interstitial pneumonia.
Topics: Administration, Intravesical; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Fat | 2010 |
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Tr | 2011 |
Treatment of ocular surface squamous cell intraepithelial neoplasia with and without mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma in Situ; Chemotherapy | 2011 |
Use of combination therapy of topical mitomycin C and cyclosporine a as an adjunct to surgery for corneal and conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Con | 2011 |
Mitomycin C therapy for corneal intraepithelial neoplasia masquerading as limbal stem cell deficiency with recurrent epithelial defect.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Carcinoma in Situ; Corneal Diseases; Diagnosis | 2011 |
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: resu
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2011 |
Pigmented squamous cell carcinoma in situ of the conjunctiva.
Topics: Amnion; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival Neoplas | 2011 |
Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; | 2012 |
Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Corneal Diseases; Eye | 2002 |
Comment on intraoperative use of mitomycin C in excision of ocular surface neoplasia with or without limbal autograft transplantation.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Co | 2002 |
[Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia].
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 2002 |
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma.
Topics: Adenocarcinoma; Administration, Intravesical; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; | 2003 |
Conjunctival intraepithelial neoplasia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in | 2003 |
Successful treatment with mitomycin C eye drops for conjunctival diffuse intraepithelial neoplasia with sebaceous features.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Female; Humans; Mitomy | 2003 |
A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma in Situ; Conj | 2004 |
Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 2004 |
Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Topics: Aged; Alternative Splicing; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma in Situ; Carci | 2004 |
[Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasm | 2004 |
Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squ | 2005 |
Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Cornea; Humans; Male; | 2006 |
[Corneal intra-epithelial neoplasia (CIN). Treatment by combined excision and antimetabolite therapy].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; | 2005 |
Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
Topics: Adenocarcinoma, Sebaceous; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; | 2006 |
Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia.
Topics: Administration, Topical; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 2006 |
Topical mitomycin C for the treatment of conjunctival tumor.
Topics: Administration, Topical; Adult; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; C | 2007 |
Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; Conjunctival Neopla | 2007 |
Corneal invasion of ocular surface squamous neoplasia after clear corneal phacoemulsification: in vivo confocal microscopy analysis.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Cornea; Corneal Diseases; Eye Neoplasms; Humans; Mal | 2008 |
A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Cystitis; Drug Evaluation; Drug Implants; Erythema; | 1983 |
Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
Topics: Adult; Aged; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1984 |
The effect of mitomycin C on superficial bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; | 1981 |
[Local chemotherapy of bladder carcinoma with mitomycin (author's transl)].
Topics: Adult; Aged; Carcinoma in Situ; Humans; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Urinar | 1982 |
Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Resistance; Female; Humans; Male; | 1982 |
[Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C].
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomyc | 1982 |
[Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer].
Topics: Antineoplastic Agents; Carcinoma in Situ; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Co | 1982 |
Bladder carcinoma--the good, the bad and the ugly.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 1996 |
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-Up Stu | 1994 |
Mitomycin C therapy for corneal intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Carcinoma in Situ; Corneal Diseases; Eye Neoplasms; Female; Humans; | 1994 |
Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Cystectomy; Female; Humans; Male; Middle Aged | 1994 |
Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1994 |
Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cisplatin; Doxorubicin; Humans; M | 1993 |
[A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Evaluation Stud | 1996 |
Successful treatment of recurrent corneal intraepithelial neoplasia with topical mitomycin C.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Corneal Diseases; Eye | 1997 |
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplas | 1997 |
Mitomycin C treatment of conjunctival intraepithelial neoplasia.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Humans; Mitomycin; Ophthalmi | 1997 |
Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Co | 1997 |
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Cor | 1998 |
Treatment of conjunctival corneal intraepithelial neoplasia with topical mitomycin C.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasm | 1999 |
Cytologic and DNA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in situ and malignant melanoma of the cornea and conjunctiva.
Topics: Aneuploidy; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival N | 1999 |
Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Diagnosis, Diff | 2000 |
Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes.
Topics: Antibodies, Monoclonal; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctiva; Conjunctival Neopl | 2000 |
Intravesical therapy for bladder cancer: empiricism at the helm.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Humans; I | 2001 |
Surgical excision, autolimbal transplantation, and mitomycin C in the treatment of conjunctival and corneal intraepithelial neoplasia.
Topics: Adult; Carcinoma in Situ; Combined Modality Therapy; Conjunctival Neoplasms; Corneal Diseases; Corne | 2001 |
[Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality | 2001 |
The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2002 |
Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in Situ; Conjunctival Neopla | 2002 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
Some aspects in treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1992 |
Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Administration S | 1992 |
Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Co | 1991 |
Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
Topics: Administration, Intravesical; Carcinoma in Situ; Cystectomy; Humans; Mitomycin; Mitomycins; Neoplasm | 1990 |
Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillary; Comb | 1990 |
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Epirubicin; Hum | 1990 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Sit | 1989 |
Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1989 |
Renal failure after intravesical mitomycin C.
Topics: Acute Kidney Injury; Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1989 |
Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study.
Topics: Administration, Topical; Adult; Aged; Buffers; Carcinoma in Situ; Cystitis; Doxorubicin; Female; Hum | 1986 |
Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters.
Topics: Animals; Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Catheters, Indwellin | 1986 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1987 |
Topical mitomycin C therapy for carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Drug Evaluation; Female; Follow-Up Studies; H | 1987 |
Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Male; M | 1987 |
[Sequential instillation therapy with mitomycin-C and adriamycin in superficial bladder tumor with special reference to fate of 43 patients achieving complete response].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1987 |
Chemotherapy for carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Combined Modality T | 1988 |
Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-U | 1985 |
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Follow-Up Studies; Hum | 1985 |
Mitomycin C in superficial bladder cancer: 24-month follow-up.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Follow-Up Studies; Humans; Mitomycin; Mitomycins; Ne | 1985 |